D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 95 Citations 36,946 567 World Ranking 4672 National Ranking 2638

Research.com Recognitions

Awards & Achievements

2017 - Fellow of the American Association for the Advancement of Science (AAAS)

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

John V. Heymach focuses on Cancer research, Lung cancer, Cancer, Internal medicine and Oncology. His biological study spans a wide range of topics, including Molecular biology, KRAS, Immunology and Epidermal growth factor receptor. His study in Lung cancer is interdisciplinary in nature, drawing from both Epithelial–mesenchymal transition, Targeted therapy, Randomized controlled trial and Adenocarcinoma.

His work carried out in the field of Cancer brings together such families of science as Blockade, CD8 and Pathology. His Internal medicine research incorporates themes from Surgery and Drug resistance. John V. Heymach interconnects Clinical trial, Phases of clinical research, Vandetanib, Carcinoma and Docetaxel in the investigation of issues within Oncology.

His most cited work include:

  • Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network (2762 citations)
  • Comprehensive genomic characterization of squamous cell lung cancers (2590 citations)
  • Molecular origins of cancer: Lung cancer (1498 citations)

What are the main themes of his work throughout his whole career to date?

Cancer research, Internal medicine, Lung cancer, Oncology and Cancer are his primary areas of study. His Cancer research study integrates concerns from other disciplines, such as Immunology, Immune system, Pathology, KRAS and Adenocarcinoma. His Chemotherapy, Radiation therapy, Phases of clinical research and Vandetanib study in the realm of Internal medicine interacts with subjects such as In patient.

The study incorporates disciplines such as Targeted therapy, Carcinoma and Immunotherapy in addition to Lung cancer. His Oncology research incorporates elements of Biomarker, Clinical trial, Lung and Cytokine. The concepts of his Cancer study are interwoven with issues in PI3K/AKT/mTOR pathway and Angiogenesis.

He most often published in these fields:

  • Cancer research (46.76%)
  • Internal medicine (38.99%)
  • Lung cancer (38.99%)

What were the highlights of his more recent work (between 2019-2021)?

  • Lung cancer (38.99%)
  • Internal medicine (38.99%)
  • Cancer research (46.76%)

In recent papers he was focusing on the following fields of study:

John V. Heymach spends much of his time researching Lung cancer, Internal medicine, Cancer research, Oncology and Cancer. His work in the fields of Lung cancer, such as Non small cell, overlaps with other areas such as Severe acute respiratory syndrome coronavirus 2. His Internal medicine study frequently links to related topics such as Gastroenterology.

His Cancer research study also includes fields such as

  • Cytotoxic T cell and Carcinoma most often made with reference to Immune system,
  • Adenocarcinoma and related DNA methylation. His Oncology research is multidisciplinary, relying on both Pembrolizumab, Nivolumab, Radiation therapy and Disease. John V. Heymach studies KRAS which is a part of Cancer.

Between 2019 and 2021, his most popular works were:

  • Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. (50 citations)
  • Comprehensive T cell repertoire characterization of non-small cell lung cancer (41 citations)
  • IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. (28 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His primary scientific interests are in Lung cancer, Internal medicine, Oncology, Cancer research and Immunotherapy. His studies deal with areas such as Immunohistochemistry, Exome sequencing, Carcinoma, Metastasis and Lung as well as Lung cancer. His biological study deals with issues like Gastroenterology, which deal with fields such as Prospective cohort study and Progression-free survival.

His studies in Oncology integrate themes in fields like Pembrolizumab, Biopsy, Clinical trial and PD-L1. The Cancer research study combines topics in areas such as Cell, DNA methylation, Immune system, Atypical adenomatous hyperplasia and Targeted therapy. His Methylation study combines topics in areas such as Carcinogenesis and Adenocarcinoma.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger.
Nature (2014)

3773 Citations

Molecular origins of cancer: Lung cancer

Roy S. Herbst;John V. Heymach;Scott M. Lippman;Scott M. Lippman.
The New England Journal of Medicine (2008)

2448 Citations

Comprehensive genomic characterization of squamous cell lung cancers

Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet.
Nature (2012)

2278 Citations

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny.
Clinical Cancer Research (2013)

906 Citations

The BATTLE Trial: Personalizing Therapy for Lung Cancer

Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)

881 Citations

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

Jianjun Zhang;Junya Fujimoto;Jianhua Zhang;David C. Wedge.
Science (2014)

764 Citations

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman;Kreshnik Zejnullahu;Christopher Michael Gale;Eugene Lifshits.
Cancer Research (2007)

713 Citations

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez.
Lancet Oncology (2016)

648 Citations

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

Limo Chen;Don Lynn Gibbons;Sangeeta Goswami;Maria Angelica Abdalla Cortez.
Nature Communications (2014)

586 Citations

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann.
Cancer Discovery (2018)

496 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing John V. Heymach

Ignacio I. Wistuba

Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center

Publications: 146

Gordon B. Mills

Gordon B. Mills

Oregon Health & Science University

Publications: 134

Pasi A. Jänne

Pasi A. Jänne

Harvard University

Publications: 115

Matthew Meyerson

Matthew Meyerson

Harvard University

Publications: 96

Ming-Sound Tsao

Ming-Sound Tsao

Princess Margaret Cancer Centre

Publications: 90

Rafael Rosell

Rafael Rosell

Autonomous University of Barcelona

Publications: 86

John D. Minna

John D. Minna

The University of Texas Southwestern Medical Center

Publications: 85

Charles M. Rudin

Charles M. Rudin

Memorial Sloan Kettering Cancer Center

Publications: 82

Kwok-Kin Wong

Kwok-Kin Wong

New York University

Publications: 78

J. Jack Lee

J. Jack Lee

The University of Texas MD Anderson Cancer Center

Publications: 76

Benjamin Besse

Benjamin Besse

Institut Gustave Roussy

Publications: 75

Gad Getz

Gad Getz

Broad Institute

Publications: 74

Suresh S. Ramalingam

Suresh S. Ramalingam

Emory University

Publications: 74

Yi-Long Wu

Yi-Long Wu

Guangdong Provincial People’s Hospital

Publications: 67

Chad J. Creighton

Chad J. Creighton

Baylor College of Medicine

Publications: 67

Mark G. Kris

Mark G. Kris

Memorial Sloan Kettering Cancer Center

Publications: 62

Trending Scientists

Amir Hussain

Amir Hussain

Edinburgh Napier University

Vladimir Zolotov

Vladimir Zolotov

IBM (United States)

Caixia Yin

Caixia Yin

Shanxi University

Philippe Maître

Philippe Maître

University of Paris-Saclay

Thomas A. Foglia

Thomas A. Foglia

United States Department of Agriculture

Gerhard Dehm

Gerhard Dehm

Max Planck Institute for Iron Research

Ulf Landegren

Ulf Landegren

Uppsala University

Steven G. Morgan

Steven G. Morgan

University of California, Davis

Takayuki Ohgushi

Takayuki Ohgushi

Kyoto University

Motoya Katsuki

Motoya Katsuki

University of Tokyo

Michael R. Gold

Michael R. Gold

University of British Columbia

Erin S. Calipari

Erin S. Calipari

Vanderbilt University

Kevin Duff

Kevin Duff

University of Utah

Jordi Bruix

Jordi Bruix

University of Barcelona

Judd W. Moul

Judd W. Moul

Duke University

Roger E. McLendon

Roger E. McLendon

Duke University

Something went wrong. Please try again later.